Chronic obstructive pulmonary disease (COPD) is characterized by a diverse array of pulmonary and nonpulmonary manifestations, but our understanding of COPD pathogenesis and the factors that influence its heterogeneity in disease presentation is poor. Despite this heterogeneity, treatment algorithms are primarily driven by a single measurement, forced expiratory volume in 1 second (FEV 1 ) as a percentage of its predicted value (FEV 1 %). In 2011, a major shift in Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment recommendations was proposed that stratifies patients with COPD on the basis of symptoms and exacerbation history. This article reviews the work reported in 2013 that enlightens our understanding of COPD with respect to COPD classification systems, phenotype, biomarker, exacerbation, and management for patients with COPD. The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies patients with chronic obstructive pulmonary disease (COPD) into four groups (A to D). We explored the characteristics, stability and relationship to outcomes of these groups within the ECLIPSE study (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) (n = 2101). Main results showed that: 1) these groups differed in several clinical, functional, imaging and biological characteristics in addition to those used for their own definition; 2) A and D groups were relatively stable over time, whereas groups B and C showed more temporal variability; 3) the risk of exacerbation over 3 years increased progressively from A to D, whereas that of hospitalisation and mortality were lowest in A, highest in D and intermediate and similar in B and C, despite the former having milder airflow limitation. The prevalence of comorbidities and persistent systemic inflammation were highest in group B. The different longitudinal behaviour of group A versus B and C versus D (each pair with similar forced expiratory volume in1 s (FEV1) values supports the 2011 GOLD proposal of assessing COPD patients by more than FEV1 only. However the assumption that symptoms do not equate to risk appears to be naïve,
Introduction
Chronic obstructive pulmonary disease (COPD) represents a spectrum of lung diseases characterised by persistent airflow limitation due to varing combinations of small-airways disease and emphysema. It is a major cause of morbidity and disability, having a prevalence of around 10% in those aged over 40 years. By 2030 COPD is predicted to have become the third-leading cause of death worldwide. This review 6 articles focuses on COPD update published in major medical journals in 2013. 
Comments
This is the first study to show the temporal stability of the four 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups compared with 2007 GOLD groups in terms of patients distribution and disease severity using ECLIPSE cohort for 3 years. Recently, some studies have examined existing COPD cohorts in different aspects of new 2011 GOLD Classification 2, 3 . This study shows that the 2011 GOLD classification had a high concordance rate for predicting exacerbations and hospitalizations compared with the 2007 GOLD classification. For follow-up periods, A and D groups did remain in their original groups, but B and C groups showed higher temporal variability. These findings suggest either disease progression or therapeutic effect. And these variability raise the concern the evidence of heterogeneity in natural history of COPD. It is not clear about untreated or mild COPD patients because this study was based on hospitalized patients.
Biomarker
The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. Carolan et al. 4 Am J Respir Care Med 2013;188: 561-6. RATIONALE: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder associated with systemic manifestations that contribute to its morbidity and mortality. Recent work suggests that biomarker signatures in the blood may be useful in evaluating COPD phenotypes and may provide insight into the pathophysiology of systemic manifestations. Adiponectin, primarily produced by fat cells, has been implicated in the pathophysiology of emphysema. OBJECTIVES: To investigate the association of adiponectin with clinical and radiologic COPD phenotypes. METHODS: Adiponectin levels were determined in 633 individuals, including 432 individuals with COPD from a cohort of former or current smokers enrolled in the COPDGene study. Univariate and multiple regression analysis were used to examine the association of adiponectin with clinical and physiologic data together with quantitative high-resolution computed tomography parameters. MEASUREMENTS AND MAIN RESULTS: Multiple regression analysis confirmed that higher plasma adiponectin levels were independently associated with emphysema, decreasing body mass index, female sex, older age, and lower percentage change in prebronchodilator/post-bronchodilator FEV1. CONCLUSIONS: The association between plasma adiponectin and computed tomography-assessed emphysema suggests a contribution of adiponectin to the development of emphysema and highlights a role for metabolic derangements in the pathophysiology of emphysema. (Carlolan et al. 4 
Comments
It is well known that blood biomarkers are associated with the phenotypes of COPD and adiponectin is one of them 5 . The expression of adiponectin was increased in bronchoalveolar lavage fluid and airway epithelial of emphysema and COPD patients and some report suggest that it was important in the pathogenesis of smoking-related lung disease 6 . For the first time, this study demonstrates that adiponectin levels are associated with computed tomography-assessed emphysema. A limitation of this study was that the majority of study population was non-Hispanic white so it is not clear in other populations.
Exacerbations
Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Molyneaux et al. 7 Am J Respir Crit Care Med 2013;188:1224-31.
RATIONALE: Rhinovirus infection is followed by significantly increased frequencies of positive, potentially pathogenic sputum cultures in chronic obstructive pulmonary disease (COPD). However, it remains unclear whether these represent de novo infections or an increased load of organisms from the complex microbial communities (microbiome) in the lower airways. OBJECTIVES: To investigate the effect of rhinovirus infection on the airway bacterial microbiome. METHODS: Subjects with COPD (n = 14) and healthy control subjects with normal lung function (n = 17) were infected with rhinovirus. Induced sputum was collected at baseline before rhinovirus inoculation and again on Days 5, 15, and 42 after rhinovirus infection and DNA was extracted. The V3-V5 region of the bacterial 16S ribosomal RNA gene was amplified and pyrosequenced, resulting in 370,849 high-quality reads from 112 of the possible 124 time points. MEASUREMENTS AND MAIN RESULTS: At 15 days after rhinovirus infection, there was a sixfold increase in 16S copy number (P = 0.007) and a 16% rise in numbers of proteobacterial sequences, most notably in potentially pathogenic Haemophilus www.e-trd.org influenzae (P = 2.7 × 10(-20)), from a preexisting community. These changes occurred only in the sputum microbiome of subjects with COPD and were still evident 42 days after infection. This was in contrast to the temporal stability demonstrated in the microbiome of healthy smokers and nonsmokers. CONCLUSIONS: After rhinovirus infection, there is a rise in bacterial burden and a significant outgrowth of Haemophilus influenzae from the existing microbiota of subjects with COPD. This is not observed in healthy individuals. Our findings suggest that rhinovirus infection in COPD alters the respiratory microbiome and may precipitate secondary bacterial infections. 
Comments
Exacerbations of COPD are frequently caused by viral or bacterial infection. Culture independent techniques investigating respiratory sample demonstrated the composition of the lower respiratory tract microbiome in COPD 8 . The authors have shown that experimental rhinovirus infection induces the clinical feature of COPD exacerbations previously 9 . Secondary bacterial infection is common after rhinovirus infection in COPD and is associated with high levels of neutrophil elastase 10 . This study is the first controlled experiment to evaluate the effect of rhinovirus infection on the airway microbiome and it shows how the study patients have a significant change in burden and community of bacteria in lower airways as a response to rhinovirus infection. We need more studies to demonstrate the clinical pertinence of these results. If these finding are proven, effective prevention and management of viral infection such as enhancing innate immunity in COPD could reduce secondary bacterial infections and use of antibiotics in virus-induced COPD exacerbations. One potential limitation is that this study subjects are mild COPD patients with a forced expiratory volume in 1 second (FEV 1 ) greater than 50% predicted. 
Short-term vs conventional glucocorticoid therapy in

Comments
Current guidelines recommend that acute exacerbations of COPD be treated with systemic corticosteroid for 7 to 14 Tuberc Respir Dis 2014;77:155-160
www.e-trd.org days but the optimal strategy for dosing and administration of these medications continues to be debated 12, 13 . Systemic steroid therapy results in moderate improvement in clinical outcomes (hospital stay, recovery of FEV 1 ) among hospitalized patients for COPD exacerbations 14 . This study shows that a 5-day course of oral prednisolone is effective and non-inferior compared with the usually recommended 10−14 days courses in terms of reexacerbations for 6months. This study included an emergency department patient but this results could like to be generalized to outpatients with mild COPD grade. Although immediate steroid-related adverse events were not different in two groups, it is likely that shorter steroid treatment course will have an influence on risk of other steroid-related adverse events.
Management
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Bateman et al. 15 
Eur Respir J 2013;42:1484-94
We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This was a multicentre, randomised, double-blind, placeboand active-controlled, 26-week trial. Patients (n = 2144) were randomised (2:2:2:2:1) to receive once-daily QVA149 (indacaterol 110 μg/glycopyrronium 50 μg), indacaterol 150 μg, glycopyrronium 50 μg, open-label tiotropium 18 μg or placebo. The primary end-point was trough forced expiratory volume in 1 s (FEV1) at week 26 for QVA149 versus its monocomponents. Secondary end-points included dyspnoea, health status, rescue medication use and safety. Trough FEV1 at week 26 was significantly improved (p<0.001) with QVA149 compared with indacaterol and glycopyrronium (least squares mean (LSM) differences 0.07 L and 0.09 L, respectively), tiotropium and placebo (LSM differences 0.08 L and 0.20 L, respectively); these beneficial effects were sustained throughout the 26-week study. QVA149 significantly improved dyspnoea and health status versus placebo (p<0.001 and p = 0.002, respectively) and tiotropium (p = 0.007 and p = 0.009, respectively) at week 26. All treatments were well tolerated. Dual bronchodilation with once-daily QVA149 demonstrated superior and clinically meaningful outcomes versus placebo and superiority versus treatment with a single bronchodilator, with a safety and tolerability profile similar to placebo, supporting the concept of fixed-dose long-acting muscarinic antagonist/long-acting β2-agonist combinations for the treatment of COPD. (Bateman et al. 15 
Comments
Current guidelines recommend treatment with one or more long-acting bronchodilator for patients with moderate or more severe COPD. Compared with tiotropium monotherapy, indacaterol plus tiotropium promoted greater bronchodilation and lung deflation with no additional safety signal 16 . QVA149, an inhaled combination of two 24-hour bronchodilators, the LABA indacaterol and the LAMA glycopyrronium, is in development for COPD. QVA149 demonstrated fast and continued bronchodilation with significant improvements compared with indacaterol monotherapy and placebo in COPD patients 17 . This study shows that additional effect of indacaterol and glycopyrronium in a combination device as dual bronchodilator sustains over 24 hours. The previous IL-LUMINATE study showed that once-daily QVA149 provides significant, sustained, and clinically meaningful improvements in lung function and symptomatic benefit compared with twice-daily salmeterol-fluticasone 18 . These results indicate the potential of dual bronchodilation as a treatment option for non-exacerbating symptomatic COPD patients. It can be used as single bronchodilator in patients with GOLD group B to D of COPD. This study shows that QVA149 is superior in clinical end points over tiotropium which is currently recommeded standard treatment in patients with GOLD groups of COPD. A limitation of this study was that it did not include all severity of COPD and excluded a recent COPD exacerbation unlike SPARK study 19 . 
Tiotropium
Comments
The UPLIFT trial showed that Tiotropium Handihaler did not report any increase in mortality or cardiovascular events but previous meta-analysis shows that Tiotropium delivered with the Respimat SoftMist Inhaler is associated with significant increased risk of mortality and cardiovascular death in patient with COPD compared with placebo 21 . These concerns about the cardiac safety of anticholinergics was continuing debate and the subgroup of COPD Respimat group with known rhythm and cardiac disorders at baseline had an especially high risk for cardiac death 22 . This TIOSPIR trial shows that Tiopropium Respimat inhaler is not associated with a higher risk of mortality than Tiotropium Handihaler. Time to first exacerbation seem to be the same for patients receiving 2.5 μg or 5 μg Tiotropium Respimat inhaler and Handihaler group. A limitation of this study was that patients with a myocardial infarction within 6 months, hospitalization for heart failure within 12 months or unstable or life-threatening arrhythmia, moderate-to-severe renal failure were excluded from enrollment in the TIOSPIR trial.
